This idea was corroborated by our previous phosphoproteomic analysis in CRC cells who identified PEAK2 as an important SRC oncogenic substrate [22] and the strong correlation between the pY413 PEAK2 level and SRC activity in established and primary culture of patient-derived CRC cell lines. The gene discussed is PRAG1; the disease is colorectal carcinoma.